OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Chagpar Discusses Surgery for Metastatic Breast Cancer

April 23rd 2013

Anees Chagpar, MD, MSc, MA, MPH, from the Smilow Cancer Hospital at Yale-New Haven, discusses the evolution of surgery as a treatment for patient with metastatic breast cancer.

Dr. Pinter-Brown on Treating CTCL With Chemotherapy

April 22nd 2013

Lauren Pinter-Brown, MD, from the University of California, Los Angeles, gives an overview of treatment with chemotherapy for patients with cutaneous T-cell lymphoma.

Dr. Andre Discusses Testing for Genomic Alterations

April 22nd 2013

Fabrice Andre, MD, PhD, from the Institut Gustave Roussy, Villejuif, France, gives an overview of methods for improving the effectiveness of genomic alteration testing in clinical trials that explore novel targeted agents in breast cancer.

Dr. Dixon on Informing a Patient Before Mastectomy

April 19th 2013

J. Michael Dixon, MBChB, MD, discusses the need for physicians to inform patients of the pros and cons before having a mastectomy.

Dr. Gomella on Radium-223 in Advanced Prostate Cancer

April 19th 2013

Leonard G. Gomella, MD, form the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the novel therapeutic radium-223, which is awaiting a decision from the FDA as a treatment for men with advanced prostate cancer.

Dr. Advani Discusses CD30 as a Target in ALCL

April 18th 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses targeting CD30 as a target and the use of brentuximab vedotin in anaplastic large-cell lymphoma.

Dr. Baselga Discusses Upcoming BOLERO-3 Data

April 18th 2013

JosÃ© Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses everolimus and the upcoming data from the BOLERO-3 trial in breast cancer.

Dr. Jennifer Brown on Ibrutinib and Idelalisib for CLL

April 17th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the treatment of chronic lymphocytic leukemia with ibrutinib, idelalisib, and other agents.

Emanuel Petricoin Describes Screening With Biomarkers

April 16th 2013

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses disease screening with biomarkers.

Dr. Ruben Mesa on Late-Stage Trials in Myelofibrosis

April 15th 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, describes three phase II and phase III trials in myelofibrosis.

Dr. Sherman Defines RAI Resistance in Thyroid Cancer

April 15th 2013

Steven I. Sherman, MD, from the MD Anderson Cancer Center, describes the need to expand the clinical definition of radioactive iodine resistance for patients with thyroid cancer.

Dr. Sledge Defines the Term "Smart" Cancer

April 15th 2013

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, defines a "smart" cancer.

Dr. Tripathy on Maintenance Therapy in Breast Cancer

April 12th 2013

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses maintenance therapy for patients with breast cancer.

Dr. Ari M. Melnick on Biomarkers in Lymphoma

April 11th 2013

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, comments on biomarkers in lymphoma.

Dr. Piccart Explains the Benefit of the IMPAKT Conference

April 11th 2013

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an overview of the IMPAKT conference.

Dr. Landgren on Carfilzomib and Pomalidomide

April 10th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.

Dr. Esserman on the I-SPY 2 Trial in Breast Cancer

April 10th 2013

Laura Esserman, MD, MBA, Professor, University of California, San Francisco, comments on the findings from the I-SPY 1 trial and the basis for the I-SPY 2 trial in patients with breast cancer.

Joan Lockhart on Fostering Oncology Nursing Education

April 9th 2013

Joan Such Lockhart, PhD, RN, AOCN, FAAN, from the Duquesne University School of Nursing, discusses resources currently available to help strengthen the oncology training of nurses.

Dr. Erba on the Diagnosis and Testing of Patients with CML

April 9th 2013

Harry Erba, MD, PhD, Professor of Medicine, Director, Hematologic Malignancy Program, University of Alabama at Birmingham, comments on the diagnosis and testing of a patient with chronic myeloid leukemia (CML).

Dr. Petrylak on Orteronel Plus Docetaxel in Prostate Cancer

April 9th 2013

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes a phase I/II study examining the safety and efficacy of orteronel in combination with docetaxel and prednisone in metastatic castration-resistant prostate cancer.